Experimental drug targets deadly transplant complication
NCT ID NCT03674047
Summary
This study is testing whether the drug ruxolitinib can help people who develop lung scarring (Bronchiolitis Obliterans Syndrome) after a stem cell transplant. The trial will enroll 50 adults to see if the medication improves their breathing and controls the underlying graft-versus-host disease. Researchers believe ruxolitinib may reduce inflammation that causes this serious complication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTHER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Cancer Center
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.